Clinical Trial Update: A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] [Phase 3]

View source ↗

Summary

Phase 3 trial comparing atezolizumab with platinum-based chemotherapy in stage IV NSCLC shows completed status with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Platinum-based chemotherapy (cisplatin or carboplatin) + pemetrexed or gemcitabine

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-02-18